Research from the University of British Columbia indicates a potential link between the use of GLP-1 agonists, including drugs like Ozempic and Wegovy (active substance semaglutide), and an increased risk of gastroparesis, pancreatitis, and ileus. These GLP-1 agonists have been widely reported in recent news for their effectiveness in weight loss. Studies have demonstrated that this class of drugs is effective in promoting weight loss. However, the new research suggests that these medications may be associated with a higher incidence of these gastrointestinal conditions. The research highlights that abdominal pain can have many different causes. Topics: #weight #loss #many Post navigation EDUCATION UPDATE ⟩ The company will invest 80,000 euros in the education of Saaremaa in three years PHOTO: Estonian football fans expressed their disapproval of Pohlak
This is concerning news, and I hope further research can clarify the potential risks associated with these medications. Reply